These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122 [TBL] [Abstract][Full Text] [Related]
3. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579 [TBL] [Abstract][Full Text] [Related]
4. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience. Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682 [TBL] [Abstract][Full Text] [Related]
6. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ J Virol; 2021 May; 95(12):. PubMed ID: 33762414 [TBL] [Abstract][Full Text] [Related]
7. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194 [TBL] [Abstract][Full Text] [Related]
8. A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL). Popmihajlov Z; Pang L; Brown E; Joshi A; Su SC; Kaplan SS; Willis ED Hum Vaccin Immunother; 2018; 14(12):2916-2920. PubMed ID: 30024827 [TBL] [Abstract][Full Text] [Related]
9. Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia. Muttucumaru R; Lau CL; Leeb A; Mills DJ; Wood N; Furuya-Kanamori L Vaccine; 2024 May; 42(13):3166-3171. PubMed ID: 38677792 [TBL] [Abstract][Full Text] [Related]
10. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. Chiyaka ET; Nghiem VT; Zhang L; Deshpande A; Mullen PD; Le P Pharmacoeconomics; 2019 Feb; 37(2):169-200. PubMed ID: 30367401 [TBL] [Abstract][Full Text] [Related]
19. Disseminated varicella zoster virus infection following live attenuated herpes zoster vaccine: descriptive analysis of reports to Australia's spontaneous vaccine pharmacovigilance system, 2016-2020. Li-Kim-Moy J; Phillips A; Morgan A; Glover C; Jayasinghe S; Hull BP; Dey A; Beard FH; Hickie M; Macartney K BMJ Open; 2023 Jan; 13(1):e067287. PubMed ID: 36707120 [TBL] [Abstract][Full Text] [Related]
20. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]